ArticleDrugs & aging1996
Diabetes mellitus in older patients. Is tight blood glucose control warranted?
Article in Drugs & aging, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a major health problem in the older population, where it is mainly of the non-insulin-dependent type [i.e. non-insulin-dependent diabetes mellitus (NIDDM)]. Epidemiological evidence and extrapolation of trial data from patients with insulin-dependent diabetes mellitus (IDDM) suggests that improving glycaemic control reduces the risk of developing microvascular complications (i.e. retinopathy, nephropathy and neuropathy) and also slows the rate of progression of these complications in patients with early disease. Macrovascular morbidity and mortality is, however, more common than microvascular disease in the older population and the evidence that improved glycaemic control significantly reduces the impact of macrovascular disease is weak. Thus, the overall benefits of tight glycaemic control are less well defined in older patients, who tend to have NIDDM, than in younger patients with IDDM. There are small but significant risks associated with tight glycaemic control in the older patient, including potentially fatal hypoglycaemia with sulphonyl-ureas and/or insulin, and fatal metformin-induced lactic acidosis. Patients at especially high risk of these complications can, however, be identified and inappropriate pharmacological intervention can be avoided.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.